Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137380 | 0.85 | ALDH1A1 (0.42) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL1119931 | 0.85 | ALDH1A1 (0.42) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL5534125 | 0.79 | ALDH1A1 (0.48) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL8075138 | 0.78 | ALDH1A1 (0.45) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL27890818 | 0.76 | TSHR (0.42) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL8568773 | 0.74 | MAPT (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL70297 | 0.74 | MEN1 (0.61) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL29627490 | 0.74 | MEN1 (0.61) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL15529884 | 0.72 | TSHR (0.39) | ALDH1A1PKMGAASMN1; SMN2MEN1 | |
| SCHEMBL15529979 | 0.72 | GPR35 (0.43) | ALDH1A1PKMGAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542723-B1 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1542723-A4 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN INC (US) | 2009-02-11 | — | — | EP | disclosed |
| US-6913748-B2 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1542723-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | Immunogen, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004016801-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | CD44, ABCG2, EPCAM | ALDH1A1 1402/4885PKM 2838/4885GAA 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.